AACR 2023 | Durvalumab and PET-directed chemoradiation in advanced esophageal cancer

Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, presents findings from a Phase Ib/II trial (NCT02962063) of durvalumab with induction FOLFOX and preoperative chemotherapy in locally advanced esophageal adenocarcinoma. Patients who were non-responders were subsequently given paclitaxel and carboplatin. High rates of pathologic response were recorded, as well as promising 2 year progression-free survival rates. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.